[32] Additionally, research into the use of biomarkers to monitor DCM progression is emerging, with raised CSF neurofilament light subunit (NF-L) and glial fibrillary acidic protein (GFAP) as well as lower amyloid β peptide being correlated with symptom duration [54]. Here, GFAP is linked to familial dilated cardiomyopathy.